| Similar Articles |
|---|
 |
Pharmaceutical Executive
October 1, 2012
William Looney |
Bidding for the Stars and Stripes As the blockbuster sales model fades, the rush is on for a new formula for growth. "Good" growth: niched, balanced, and sustainable; with high margins from protected pricing; more patient-friendly than patent-centric; and where revenues draw from a deep reservoir of unmet medical need.   |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
December 1, 2010
William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China. |
Pharmaceutical Executive
November 1, 2011
William Looney |
R&D Costs: It's Industry's Problem If high prices that lower access are attributable to a flawed R&D model, can the pharmaceutical industry embrace delivering better results at lower costs. |
Pharmaceutical Executive
November 1, 2013
William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive
October 1, 2012
Peter O'Donnell |
Richard Bergstrom -- Europe's Medicine Man The new head of the European Federation of Pharmaceutical Industries and Associations faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics. |
Pharmaceutical Executive
September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
October 1, 2010 |
Nobel Laureate Elie Wiesel Exclusive Interview Ethical behavior can be a bridge-builder in an era where Big Pharma needs to find new partners. Is it up to the challenge? |
Pharmaceutical Executive
May 1, 2012
William Looney |
Seeding Beyond the Base The pharmaceutical industry's reputation as a growth industry no one wants to pay for is more secure than ever. |
Pharmaceutical Executive
October 1, 2006
Sarah Houlton |
Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China. |
Pharmaceutical Executive
May 1, 2011
William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive
July 1, 2011 |
Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy. |
